Form 4: Avidity Biosciences Chief Scientific Officer Receives Stock and Options

Avidity Biosciences' Chief Scientific Officer, W. Michael Flanagan, was granted 25,000 restricted stock units and options to purchase 50,000 shares of common stock on January 6, 2025.

Summary

• W. Michael Flanagan, Chief Scientific Officer of Avidity Biosciences, received 25,000 restricted stock units (RSUs) on January 6, 2025.
• These RSUs will vest in four equal installments annually starting January 6, 2026, contingent on his continued employment.
• Flanagan also received options to purchase 50,000 shares of Avidity Biosciences common stock at an exercise price of $31.42.
• These options vest monthly over four years, becoming fully vested on January 6, 2029.
• Following these transactions, Flanagan directly owns 97,647 shares of common stock and options for 50,000 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard positive practice of incentivizing key personnel with equity, which is generally viewed favorably by investors.

Positives

• The grant of stock and options aligns the Chief Scientific Officer's interests with those of the shareholders.
• The vesting schedule for both the RSUs and options encourages long-term commitment from the executive.
• The grant of equity may serve as an incentive for the executive to drive company performance.

Risks

• The value of the stock options is dependent on the future performance of the company's stock price.
• The vesting of the RSUs and options is contingent on the executive's continued employment, creating a potential risk of loss if employment is terminated.

Industry Context

This type of equity grant is a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Equity grants, including stock options and restricted stock units, are standard compensation practices for executives in the biotech industry.
• Vesting schedules, such as the four-year vesting period for options and annual vesting for RSUs, are typical in similar companies.
• Companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals also use similar equity-based compensation to align executive interests with shareholder value.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, executive compensation, insider trading, equity, vesting, Avidity Biosciences, RNA